Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Subspecialties Retina, Business and Innovation, Practice Management, Diabetes

Pascal Synthesis Photocoagulator

sponsored by Iridex

The Pascal® Laser revolutionized how retina laser treatments were performed when it was launched in 2005. Its speed, precision, and ease of use was a quantum leap in ophthalmic laser technology and was quickly adopted by the retina community – earning Pascal the title of gold standard for the treatment of diabetic retinopathy and solidifying its position as the market leader in pattern-scanning lasers. Pascal has evolved alongside the laser industry; the ergonomic Pascal Synthesis, developed by Topcon, is the technology’s fourth iteration and has features specifically requested by doctors and clinical staff.

Now part of the Iridex laser family, the Pascal Synthesis is one of the most clinically efficient and versatile laser systems ever designed. Its reduced power and short pulses make procedures more comfortable for patients (1) – and its patented four-fiber beam delivery system enables even burns over varying elevations and with larger patterns. Multiple laser spots can be delivered with a single footswitch depression and the aiming beam displays the pattern for added precision. In addition, the system’s new, intuitive software and high-speed pattern generators make it easy to handle large patient volumes.

Pascal features an array of treatment options – whether it’s single spot, patterns, laser indirect, subthreshold retina treatments with Endpoint Management, or Pattern Scanning Laser Trabeculoplasty. The platform’s innovative features make Pascal Synthesis an essential tool for retina practices, and continue to set the standard in pattern-scanning lasers. 

Learn more at iridexretina.com

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. M Nagpal et al., Retina, 30, 452. PMID: 20216293.
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register